Mandrola’s Top 10 Cardiology Stories of 2019
It’s probably no surprise that ISCHEMIA and the EXCEL controversy make John Mandrola’s annual list for 2019. He also found good news in heart failure and has words of caution for TAVR expansion.
Related Articles
STRONG HF – A Positive Trial that Does Not Help Clinical Medicine
The Study of the Week explores the larger question of what are trials for?
Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still…
Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still…
TEER in Functional MR: Data Deluge, but No Easy Answers
A third trial of transcatheter edge-to-edge repair in patients with functional mitral regurgitation doesn’t make for easy patient selection writes John Mandrola, MD.
TEER in Functional MR: Data Deluge, but No Easy Answers
A third trial of transcatheter edge-to-edge repair in patients with functional mitral regurgitation doesn’t make for easy patient selection writes John Mandrola, MD.
Mandrola’s Five Big Trials to Look for at ESC 2024
A sham trial of AF ablation, finerenone in heart failure, and transcatheter edge-to-edge repair of functional mitral regurgitation are among the trials that caught cardiologist…
Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still…
Aug 23 2024 This Week in Cardiology
Episode · This Week in Cardiology · Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and…
Independent NPs and PAs: A Doc’s View
Nurse practitioners and physician assistants increasingly manage patient care independently. While professional physician organizations cry foul, this doctor is not alarmed.
Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease | NEJM
Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study,…